Sign inJoin waitlistJoin the waitlist

Shaji Kumar

Research Chair, Division of Hematology, Department of Internal Medicine · Mayo Clinic College of Medicine and Science

Credentials: · · ·

History

Division of Hematology Department · Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present

Hematology and Medical Oncology
Mayo Clinic College of Medicine and Science
1998–2001
Medical Oncology
1996–1998
Internal Medicine
Internal Medicine All-India Institute of Medical Sciences
1993–1996
ALL INDIA INST OF MED SCI, ANSARI NAGAR, NEW DELHI, DELHI
1989–1993

Research

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Review · The Lancet Oncology · 2014 · 3,783 citations
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Review · Leukemia · 2022 · 3,300 citations
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Review · The Lancet Oncology · 2016 · First of 40 authors · Corresponding · 2,602 citations

Angela Dispenzieri
543 papers
Morie Gertz
504 papers
SR
Sundararajan Rajkumar
478 papers
ML
Martha Lacy
407 papers
Francis Buadi
396 papers
David Dingli
368 papers
Suzanne Hayman
360 papers
Prashant Kapoor
338 papers
RK
Robert Kyle
334 papers
Nelson Leung
299 papers
Wilson Gonsalves
285 papers · 10 as a fellow
Taxiarchis Kourelis
264 papers · 12 as a fellow

Grants

Onset and Biomarkers for Progression of Monoclonal Gammopathies
National Cancer Institute · R01
PI · $3.2M · Mayo Clinic Rochester
2012–2027
Impact of Genetic Susceptibility Along the Continuum from MGUS to MM
National Cancer Institute · U01
PI · $3.4M · Mayo Clinic Rochester
2022–2027
Mayo Clinic Comprehensive Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $2.3M · Mayo Clinic Rochester
1997–2024
Overcoming Drug Resistance in Multiple Myeloma
National Cancer Institute · U54
PI · $1.6M · Mayo Clinic Arizona
2017–2023

Clinical trials

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
Principal investigator · Active not recruiting · Phase 1
Mayo Clinic
2024–2027
A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma
Principal investigator · Completed
Mayo Clinic
2023–2025
Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma
Principal investigator · Completed
Mayo Clinic
2023–2025
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Principal investigator · Active not recruiting · Phase 2
Mayo Clinic
2022–2028